Candriam S.C.A. Apellis Pharmaceuticals, Inc. Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 680,058 shares of APLS stock, worth $19.1 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

680,058

Previous 543,035 25.23%

Holding current value

$19.1 Million

Previous $20.8 Million 5.85%

% of portfolio

0.11%

Previous 0.13%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$28.84 - $41.15 $3.95 Million - $5.64 Million	137,023 Added 25.23%	680,058 $19.6 Million
Q2 2024 Aug 05, 2024	SELL	$38.07 - $59.71 $1.59 Million - $2.5 Million	-41,890 Reduced 7.16%	543,035 $20.8 Million
Q1 2024 May 03, 2024	BUY	$55.39 - $72.47 $13.7 Million - $17.9 Million	247,418 Added 73.31%	584,925 $34.4 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $408,540 - $713,019	11,000 Added 3.37%	337,507 $20.2 Million
Q2 2023 Aug 08, 2023	SELL	$76.68 - $93.31 $8.97 Million - $10.9 Million	-117,000 Reduced 26.38%	326,507 $29.7 Million
Q1 2023 May 12, 2023	BUY	$46.59 - $66.96 $7.69 Million - $11 Million	165,000 Added 59.24%	443,507 $29.3 Million
Q4 2022 Feb 13, 2023	SELL	$43.24 - $61.04 $2.81 Million - $3.97 Million	-65,000 Reduced 18.92%	278,507 $14.4 Million
Q3 2022 Nov 10, 2022	SELL	$44.76 - $69.66 $12.2 Million - $18.9 Million	-271,950 Reduced 44.19%	343,507 $23.5 Million
Q2 2022 Aug 03, 2022	BUY	$35.07 - $59.21 $5.24 Million - $8.84 Million	149,362 Added 32.05%	615,457 $27.8 Million
Q1 2022 May 13, 2022	SELL	$35.46 - $54.12 $8.1 Million - $12.4 Million	-228,330 Reduced 32.88%	466,095 $23.7 Million
Q4 2021 Feb 10, 2022	BUY	$30.74 - $49.16 $13.5 Million - $21.6 Million	439,395 Added 172.29%	694,425 $32.8 Million
Q3 2021 Nov 09, 2021	SELL	$31.4 - $69.84 $1.96 Million - $4.35 Million	-62,285 Reduced 19.63%	255,030 $8.41 Million
Q2 2021 Jul 20, 2021	SELL	$40.9 - $64.9 $9.74 Million - $15.5 Million	-238,059 Reduced 42.86%	317,315 $20.1 Million
Q4 2020 Jan 22, 2021	SELL	$30.79 - $57.2 $18.3 Million - $33.9 Million	-593,491 Reduced 51.66%	555,374 $31.8 Million
Q3 2020 Oct 19, 2020	SELL	$25.89 - $33.65 $1.59 Million - $2.07 Million	-61,533 Reduced 5.08%	1,148,865 $34.7 Million
Q2 2020 Jul 23, 2020	BUY	$24.8 - $38.49 $20.3 Million - $31.5 Million	818,198 Added 208.62%	1,210,398 $39.5 Million
Q4 2019 Jan 21, 2020	SELL	$22.1 - $30.8 $939,250 - $1.31 Million	-42,500 Reduced 9.78%	392,200 $12,000
Q3 2019 Oct 21, 2019	SELL	$24.09 - $32.18 $2.24 Million - $2.99 Million	-93,000 Reduced 17.62%	434,700 $10,000
Q4 2018 Feb 14, 2019	BUY	$11.47 - $18.71 $137,640 - $224,520	12,000 Added 2.33%	527,700 $6.96 Million
Q3 2018 Nov 07, 2018	BUY	$16.57 - $21.03 $4.57 Million - $5.8 Million	275,700 Added 114.88%	515,700 $9.17 Million
Q2 2018 Aug 14, 2018	BUY	$19.63 - $30.0 $2.28 Million - $3.48 Million	116,000 Added 93.55%	240,000 $5.28 Million
Q1 2018 May 09, 2018	BUY	$14.01 - $26.02 $98,070 - $182,140	7,000 Added 5.98%	124,000 $2.74 Million
Q4 2017 Feb 07, 2018	BUY	$12.71 - $21.7 $1.49 Million - $2.54 Million	117,000	117,000 $2.54 Million

Others Institutions Holding APLS

# of Institutions

309

Shares Held

115M

Call Options Held

3.37M

Put Options Held

816K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.08B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account